Table 2. Gene showed most biased mutation (fraction of mutant cell lines is more in resistant than in sensitive cell lines) for each anticancer drug.

Drug	Gene	Total	Resistant Cell Lines			Sensitive Cell Lines			Fraction Difference
			Mutant	Total	Fraction	Mutant	Total	Fraction
17AAG	SPEN	447	21	97	0.216	38	350	0.109	0.107
AEW541	MLL3	447	128	430	0.298	1	17	0.059	0.239
AZD0530	MAP3K1	448	339	434	0.781	8	14	0.571	0.21
AZD6244	TP53	447	249	382	0.652	30	65	0.462	0.19
Erlotinib	TTN	447	321	438	0.733	3	9	0.333	0.4
Irinotecan	KRAS	279	30	97	0.309	33	182	0.181	0.128
L685458	KRAS	435	90	423	0.213	0	12	0	0.213
LBW242	MLL3	435	125	423	0.296	1	12	0.083	0.213
Lapatinib	MSH3	447	148	434	0.341	2	13	0.154	0.187
Nilotinib	LRP1B	370	109	358	0.304	0	12	0	0.304
Nutlin3	TP53	448	280	446	0.628	0	2	0	0.628
PD0325901	TP53	448	223	330	0.676	57	118	0.483	0.193
PD0332991	MAP3K1	384	295	379	0.778	2	5	0.4	0.378
PF2341066	PDE4DIP	448	241	436	0.553	2	12	0.167	0.386
PHA665752	NCOA3	447	200	444	0.45	0	3	0	0.45
PLX4720	TP53	440	274	431	0.636	1	9	0.111	0.525
Paclitaxel	GPR112	447	54	71	0.761	241	376	0.641	0.12
Panobinostat	HSPA4	444	2	4	0.5	4	440	0.009	0.491
RAF265	KRAS	408	81	355	0.228	4	53	0.075	0.153
Sorafenib	CREB3L2	447	226	439	0.515	1	8	0.125	0.39
TAE684	CSMD3	448	105	416	0.252	2	32	0.062	0.19
TKI258	AAK1	448	241	441	0.546	1	7	0.143	0.403
Topotecan	KRAS	448	60	220	0.273	32	228	0.14	0.133
ZD6474	CREB3L2	440	224	430	0.521	2	10	0.2	0.321